Get the latest Science News and Discoveries

Insilico Medicine receives IND approval from FDA for novel MAT2A inhibitor ISM3412 - EurekAlert


Clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine (“Insilico”) announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ISM3412, a small molecule inhibitor of MAT2A for the potential treatment of MTAP deleted cancers designed with Insilico’s generative AI platform. 

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of IND approval

IND approval

Photo of EurekAlert

EurekAlert

Photo of FDA

FDA

Related news:

News photo

Barley plants fine-tune their root microbial communities through sugary secretions - EurekAlert

News photo

Enhancing fermented sausage quality: a comprehensive review of gel formation mechanisms and the role of lactic acid ... - EurekAlert

News photo

Revolutionizing Mei (Prunus mume) breeding: genomic insights into ornamental and cold resistance traits - EurekAlert